CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back

The article by Mendel and colleagues, published in the January 1, 2003, issue of Clinical Cancer Research, described their novel preclinical approach to developing a thorough understanding of the exposure-activity relationship for sunitinib, a multitargeted receptor tyrosine kinase inhibitor being d...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 21; no. 11; pp. 2415 - 2417
Main Authors Mendel, Dirk B, Cherrington, Julie M, Laird, A Douglas
Format Journal Article
LanguageEnglish
Published United States 01.06.2015
Subjects
Anniversaries and Special Events
History, 21st Century
Humans
Indoles - history
Indoles - therapeutic use
Neoplasms - drug therapy
Neoplasms - history
Pyrroles - history
Pyrroles - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:The article by Mendel and colleagues, published in the January 1, 2003, issue of Clinical Cancer Research, described their novel preclinical approach to developing a thorough understanding of the exposure-activity relationship for sunitinib, a multitargeted receptor tyrosine kinase inhibitor being developed for oncology therapy. This work successfully set exposure guidelines to identify a biologically active dose in early clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-14-2557